z-logo
Premium
Survival rates of biological therapies for psoriasis treatment in real‐world clinical practice: A Canadian multicentre retrospective study
Author(s) -
Marinas Joseph EC,
Kim Whan B,
Shahbaz Ali,
Qiang Judy K,
Greaves Simon,
Yeung Jensen
Publication year - 2018
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.12548
Subject(s) - medicine , ustekinumab , etanercept , adalimumab , infliximab , psoriasis , log rank test , survival analysis , retrospective cohort study , hazard ratio , clinical trial , dermatology , disease , confidence interval , rheumatoid arthritis
Background/Objectives Data on biologic drug survival in real‐world psoriasis treatment are limited. There is a need to evaluate long‐term trends of biologic use outside the realm of clinical trials. Methods A multicentre chart review was conducted with patients' data from September 2005 to September 2014. Kaplan–Meier plot analysis was used to determine 5‐year drug survival rates. A log–rank test was used to compare the rates of drug survival between the studied biologics. Results For the 398 patients and 545 treatment series analysed, 1, 2, 3, 4 and 5‐year survival rates were 0.826, 0.687, 0.563, 0.475 and 0.420 with etanercept; 0.804, 0.648, 0.553, 0.508 and 0.508 with adalimumab; 0.838, 0.664, 0.554, 0.485 and 0.382 with infliximab; and 0.914, 0.856, 0.800, 0.755 and 0.755 with ustekinumab, respectively. A statistically significant difference was seen between ustekinumab and the other three biologics. Conclusion A progressive decrease in treatment adherence was seen with all four biologics, as expected, but the survival rate of ustekinumab was highest.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here